 |
|
Recurrent Visual Field Defect and Ischemic Optic Neuropathy Associated With Tadalafil Rechallenge
Arch Ophthalmol. 2005;123:400-401.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Tadalafil, a selective cyclic guanosine monophosphate (cGMP)–specific phosphodiesterase type 5 (PDE5) inhibitor, enhances penile erectile function in men. Nitric oxide along with cGMP promotes blood flow to and dilation of smooth muscle in the corpus cavernosum of the penis. Phosphodiesterase type 5 inhibitors prevent degradation of cGMP to potentiate erectile function. Tadalafil (Cialis; Lily ICOS LLC, Indianapolis, Ind) is one of the PDE5 inhibitors approved for erectile dysfunction, which also include sildenafil citrate (Viagra; Pfizer, Inc, New York, NY) and vardenafil hydrochloride (Levitra; Bayer AG, Leverkusen, Germany, and GlaxoSmithKline, Uxbridge, England).
The package insert for tadalafil describes adverse ophthalmic reactions that include blurred vision, changes in color vision, conjunctivitis, eye pain, tearing, and swelling of the eyelids. Some reports suggest that sildenafil use may be associated with nonarteritic anterior ischemic optic neuropathy (NAION).1-3 We describe a patient who took tadalafil 5 times in 1 month. He developed transient inferior visual . . . [Full Text of this Article] Report of a Case
Comment
AUTHOR INFORMATION
Kathryn Bollinger, MD, PhD;
Michael S. Lee, MD
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
Danesh-Meyer and Levin
Br. J. Ophthalmol. 2007;91:1551-1555.
ABSTRACT
| FULL TEXT
Can erectile dysfunction drug use lead to ischaemic optic neuropathy?
Pomeranz
Br. J. Ophthalmol. 2006;90:127-128.
FULL TEXT
BJO at a glance
Hoyt
Br. J. Ophthalmol. 2006;90:127-127.
FULL TEXT
|
